A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

May 21, 2026 updated by: Bristol-Myers Squibb

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

130

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: First line of the email MUST contain NCT # and Site #.

Study Contact Backup

  • Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  • Phone Number: 855-907-3286
  • Email: Clinical.Trials@bms.com

Study Locations

  • Australia
    • New South Wales
      • Campbelltown, New South Wales, Australia, 2560
        • Recruiting
        • GenesisCare - Campbelltown
        • Contact:
          • Jessica Smith, Site 0057
          • Phone Number: +61 2 4632 5500
      • Camperdown, New South Wales, Australia, 2050
        • Recruiting
        • Chris O'Brien Lifehouse
        • Contact:
          • Steven Kao, Site 0059
          • Phone Number: +61 2 85140594
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Recruiting
        • Princess Alexandra Hospital
        • Contact:
          • Wen Xu, Site 0058
          • Phone Number: (+61) 731762111
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Recruiting
        • GenesisCare - St Andrew's
        • Contact:
          • VY Broadbridge, Site 0097
          • Phone Number: +61 8 8380 1300
  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 101149
        • Recruiting
        • Beijing Chest Hospital,Capital Medical University
        • Contact:
          • Zhe Liu, Site 0039
          • Phone Number: 010-8909303
    • Fujian
      • Xiamen, Fujian, China, 361003
        • Recruiting
        • The First Affiliated Hospital of Xiamen University
        • Contact:
          • Feng Ye, Site 0055
          • Phone Number: 8613860458889
    • Guangxi
      • Nanning, Guangxi, China, 530201
        • Recruiting
        • Guangxi Medical University Affiliated Tumor Hospital
        • Contact:
          • Wenhua Zhao, Site 0050
          • Phone Number: 13878873120
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Recruiting
        • The First Affiliated Hospital of Nanchang University
        • Contact:
          • Longhua Sun, Site 0043
          • Phone Number: 8613698091288
    • Shandong
      • Jinan, Shandong, China, 250117
        • Recruiting
        • Shandong Cancer Hospital
        • Contact:
          • Ligang Xing, Site 0054
          • Phone Number: 86-15553181309
      • Linyi, Shandong, China, 276001
        • Recruiting
        • Linyi Cancer Hospital
        • Contact:
          • Jianhua Shi, Site 0044
          • Phone Number: +8615963998868
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310016
        • Recruiting
        • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
        • Contact:
          • Enguo Chen, Site 0049
          • Phone Number: 13588706779
      • Linhai, Zhejiang, China, 317000
        • Recruiting
        • Taizhou Hospital of Zhejiang Province
        • Contact:
          • Dongqing LV, Site 0053
          • Phone Number: 13867622009
  • France
      • Paris, France, 75248
        • Recruiting
        • Institut Curie
        • Contact:
          • nicolas girard, Site 0107
          • Phone Number: +33624456290
      • Paris, France, 75970
        • Recruiting
        • Hôpital Tenon
        • Contact:
          • Jacques Cadranel, Site 0027
          • Phone Number: 33156016531
      • Paris, France, 75014
        • Recruiting
        • Hopitaux Universitaires Paris Centre-Hopital Cochin
        • Contact:
          • Marie Wislez, Site 0013
          • Phone Number: 33158413091
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, France, 13385
        • Not yet recruiting
        • Local Institution - 0045
        • Contact:
          • Site 0045
    • Isère
      • La Tronche, Isère, France, 38700
        • Recruiting
        • Chu Grenoble Alpes
        • Contact:
          • Denis Moro-Sibilot, Site 0015
          • Phone Number: 33476765467
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, France, 44800
        • Recruiting
        • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
        • Contact:
          • Elvire Pons-Tostivint, Site 0012
          • Phone Number: +33676133810
    • Meurthe-et-Moselle
      • Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France, 54511
        • Recruiting
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
        • Contact:
          • Bertrand Mennecier, Site 0095
          • Phone Number: 33383154653
    • Rhône
      • Bron, Rhône, France, 69677
        • Recruiting
        • Hospices Civils de Lyon - Hôpital Louis Pradel
        • Contact:
          • Michael Duruisseaux, Site 0041
          • Phone Number: 33427857700
    • Île-de-France Region
      • Paris, Île-de-France Region, France, 75014
        • Recruiting
        • Groupe hospitalier Paris saint Joseph
        • Contact:
          • Carole Helissey-Danis, Site 0096
          • Phone Number: 33330143985319
  • Germany
      • Cologne, Germany, 50937
        • Recruiting
        • Universitaetsklinikum Koeln
        • Contact:
          • Juergen Wolf, Site 0067
          • Phone Number: +4922147889050
      • Würzburg, Germany, 97080
        • Recruiting
        • Universitaetsklinikum Wuerzburg
        • Contact:
          • Elisabeth Goebeler, Site 0065
          • Phone Number: 4993120140155
    • Bavaria
      • München, Bavaria, Germany, 81377
        • Recruiting
        • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
        • Contact:
          • Diego Kauffmann-Guerrero, Site 0068
          • Phone Number: 4989440052590
    • Hesse
      • Frankfurt am Main, Hesse, Germany, 60590
        • Recruiting
        • Universitätsklinikum Frankfurt Goethe-Universität
        • Contact:
          • Fabian Acker, Site 0070
          • Phone Number: 0000
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Germany, 06120
        • Recruiting
        • Krankenhaus Martha-Maria Halle-Dölau
        • Contact:
          • Miriam Moeller, Site 0066
          • Phone Number: 00493455591440
  • Italy
      • Bologna, Italy, 40138
        • Recruiting
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • Contact:
          • Francesco Gelsomino, Site 0024
          • Phone Number: +390512142203
      • Milan, Italy, 20133
        • Recruiting
        • Fondazione IRCCS Istituto Nazionale dei Tumori
        • Contact:
          • Claudia Proto, Site 0019
          • Phone Number: 390223903829
    • Campania
      • Naples, Campania, Italy, 80131
        • Recruiting
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale
        • Contact:
          • Alessandro Morabito, Site 0020
          • Phone Number: 390817770291
      • Naples, Campania, Italy, 80131
        • Recruiting
        • AOU della Campania Luigi Vanvitelli
        • Contact:
          • Carminia Maria Della Corte, Site 0026
          • Phone Number: 3929160541
    • Lombardy
      • Monza, Lombardy, Italy, 20900
        • Recruiting
        • Fondazione IRCCS San Gerardo dei Tintori
        • Contact:
          • Diego Cortinovis, Site 0025
          • Phone Number: 390392333683
    • Milano
      • Milan, Milano, Italy, 20162
        • Recruiting
        • ASST Grande Ospedale Metropolitano Niguarda
        • Contact:
          • Giulio Cerea, Site 0022
          • Phone Number: 390264442291
    • Veneto
      • Padova, Veneto, Italy, 35128
        • Recruiting
        • Istituto Oncologico Veneto IRCCS
        • Contact:
          • Giulia Pasello, Site 0023
          • Phone Number: 39498215620
  • Japan
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Recruiting
        • National Cancer Center Hospital East
        • Contact:
          • Hibiki Udagawa, Site 0092
          • Phone Number: 81471331111
    • Miyagi
      • Sendai, Miyagi, Japan, 9810914
        • Recruiting
        • Sendai Kousei Hospital
        • Contact:
          • Shunichi Sugawara, Site 0094
          • Phone Number: 81227288000
    • Osaka
      • Hirakata, Osaka, Japan, 573-1191
        • Recruiting
        • Kansai Medical University Hospital
        • Contact:
          • Takayasu Kurata, Site 0093
          • Phone Number: 81728042503
  • Poland
      • Prabuty, Poland, 82-550
        • Recruiting
        • Szpital Specjalistyczny w Prabutach Spolka z o.o.
        • Contact:
          • Anna Lowczak, Site 0064
          • Phone Number: +48503022396
    • Masovian Voivodeship
      • Wieliszew, Masovian Voivodeship, Poland, 05-135
        • Recruiting
        • Mazowiecki Szpital Onkologiczny
        • Contact:
          • Renata Biernacka, Site 0060
          • Phone Number: 509120229
  • Romania
      • Bucharest, Romania, 020335
        • Recruiting
        • Centrul de Diagnostic si Tratament Provita
        • Contact:
          • Mircea Dediu, Site 0040
          • Phone Number: 0040744432443
      • Cluj-Napoca, Romania, 400015
        • Recruiting
        • Institutul Oncologic Cluj
        • Contact:
          • Tudor Ciuleanu, Site 0034
          • Phone Number: 40745646368
      • Iași, Romania, 700106
        • Recruiting
        • S.C. Centrul de Oncologie Euroclinic S.R.L.
        • Contact:
          • Constantin Volovat, Site 0030
          • Phone Number: 40746110096
      • Iași, Romania, 700483
        • Recruiting
        • Institutul Regional de Oncologie
        • Contact:
          • Dana Clement, Site 0032
          • Phone Number: 40744692062
    • Bucharest
      • Bucharest, Bucharest, Romania, 022338
        • Recruiting
        • Institutul Oncologic Bucuresti "Prof. Dr. Alexandru Trestioreanu"
        • Contact:
          • Aurelia Alexandru, Site 0029
          • Phone Number: 40723289606
    • Cluj
      • Florești, Cluj, Romania, 407280
        • Recruiting
        • SC Radiotherapy Center Cluj SRL
        • Contact:
          • Andrei Ungureanu, Site 0036
          • Phone Number: 40742206212
    • Dolj
      • Craiova, Dolj, Romania, 200542
        • Recruiting
        • Centrul de Oncologie "Sfântul Nectarie"
        • Contact:
          • Michael Schenker, Site 0031
          • Phone Number: 40727774974
  • Spain
      • Málaga, Spain, 29011
        • Recruiting
        • H.R.U Málaga - Hospital General
        • Contact:
          • Manuel Cobo-Dols, Site 0075
          • Phone Number: 00349422033350000
      • Seville, Spain, 41013
        • Recruiting
        • Hospital Universitario Virgen del Rocio
        • Contact:
          • Reyes Bernabe Caro, Site 0089
          • Phone Number: 34955015273
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitari i Politecnic La Fe
        • Contact:
          • Oscar Juan Vidal, Site 0072
          • Phone Number: 34961245877
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron
        • Contact:
          • Enriqueta Felip Font, Site 0074
          • Phone Number: 34932746077
      • Hospitalet, Barcelona [Barcelona], Spain, 08907
        • Recruiting
        • Institut Catala d'Oncologia - L'Hospitalet
        • Contact:
          • Ernest Nadal Alforja, Site 0073
          • Phone Number: 34932607283
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramon y Cajal
        • Contact:
          • Maria Eugenia Olmedo Garcia, Site 0077
          • Phone Number: 34913368263
      • Madrid, Madrid, Comunidad de, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
        • Contact:
          • Luis Paz-Ares Rodriguez, Site 0071
          • Phone Number: +34913908546
      • Madrid, Madrid, Comunidad de, Spain, 28046
        • Recruiting
        • Hospital Universitario La Paz
        • Contact:
          • Javier de Castro Carpeno, Site 0076
          • Phone Number: 34917277516
  • Sweden
    • Stockholms Län [se-01]
      • Solna, Stockholms Län [se-01], Sweden, 171 64
        • Recruiting
        • Karolinska Universitetssjukhuset Solna
        • Contact:
          • Luigi DePetris, Site 0002
          • Phone Number: 45 08-123 79517
    • Västra Götalands Län [se-14]
      • Gothenburg, Västra Götalands Län [se-14], Sweden, 413 45
        • Recruiting
        • Sahlgrenska Universitetssjukhuset
        • Contact:
          • Andreas Hallqvist, Site 0003
          • Phone Number: +46735-985411
  • United Kingdom
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • Recruiting
        • Freeman Hospital
        • Contact:
          • Alastair Greystoke, Site 0004
          • Phone Number: +44 (0)191 213 8450
    • England
      • Birmingham, England, United Kingdom, B15 2TH
        • Recruiting
        • Queen Elizabeth Hospital Birmingham
        • Contact:
          • Gary Middleton, Site 0069
          • Phone Number: +44 121 3718783
    • London, City of
      • London, London, City of, United Kingdom, w1g 6ad
        • Recruiting
        • Sarah Cannon Research Institute UK
        • Contact:
          • Elisa Fontana, Site 0008
          • Phone Number: +44 (0) 203 219 5234
  • United States
    • Alaska
      • Anchorage, Alaska, United States, 99508
        • Recruiting
        • Alaska Oncology and Hematology
        • Contact:
          • Steven Liu, Site 0088
          • Phone Number: 907-257-9851
    • Idaho
      • Boise, Idaho, United States, 83712
        • Not yet recruiting
        • Local Institution - 0099
        • Contact:
          • Site 0099
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Dana-Farber Cancer Institute
        • Contact:
          • Pasi Janne, Site 0090
          • Phone Number: 617-632-6036
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Recruiting
        • Karmanos Cancer Institute
        • Contact:
          • Hirva Mamdani, Site 0100
          • Phone Number: 909-525-0093
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine
        • Contact:
          • Anjali Rohatgi, Site 0104
          • Phone Number: 314-747-1171
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center
        • Contact:
          • Kathryn Arbour, Site 0018
          • Phone Number: 646-608-3792
      • Shirley, New York, United States, 11967
        • Not yet recruiting
        • Local Institution - 0079
        • Contact:
          • Site 0079
    • Ohio
      • Canton, Ohio, United States, 44718
        • Recruiting
        • Gabrail Cancer Center
        • Contact:
          • Nashat Gabrail, Site 0091
          • Phone Number: 330-417-8231
    • Oregon
      • Portland, Oregon, United States, 97239
        • Recruiting
        • Oregon Health and Science University
        • Contact:
          • Jeremy Cetnar, Site 0103
          • Phone Number: 503-494-3840
      • Portland, Oregon, United States, 97213
        • Recruiting
        • Providence Portland Medical Center
        • Contact:
          • Rachel Sanborn, Site 0098
          • Phone Number: 503-215-5696
    • Washington
      • Seattle, Washington, United States, 98109
        • Recruiting
        • Fred Hutchison Cancer Center
        • Contact:
          • Lei Deng, Site 0078
          • Phone Number: 206-606-4801
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • Medical College of Wisconsin
        • Contact:
          • Jonathan Thompson, Site 0084
          • Phone Number: 920-202-1555

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation.
  • Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
  • At least 1 measurable lesion as per RECIST v1.1.
  • Documented radiographic disease progression on or after the most recent line of treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
  • Capability to swallow tablets intact (without chewing or crushing).

Exclusion Criteria

  • Active brain metastases or carcinomatous meningitis.
  • History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
  • Prior treatment with a PRMT5 or MAT2A inhibitor.
  • Known severe hypersensitivity to study treatment and/or any of its excipients.
  • Other protocol-defined inclusion/exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm A: BMS-986504 Dose 1
Drug: BMS-986504
Specified dose on specified days
Other Names:
  • MRTX1719
  • Navlimetostat
Experimental: Arm B: BMS-986504 Dose 2
Drug: BMS-986504
Specified dose on specified days
Other Names:
  • MRTX1719
  • Navlimetostat

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
OR is defined as confirmed complete response (CR) or partial response (PR)
Up to 3 years after the last participant's last dose of study treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants who achieve disease control (DC) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
DC is defined as Best Overall Response (BOR) of confirmed CR, confirmed PR, or stable disease (SD)
Up to 3 years after the last participant's last dose of study treatment
Number of participants who achieve clinical benefit (CB) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
CB is defined as BOR of confirmed CR, confirmed PR, or SD for at least 6 months after start of treatment
Up to 3 years after the last participant's last dose of study treatment
Duration of response (DOR) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
DOR is defined as the time between the date of the first documentation of objective tumor response (CR or PR) and the date of disease progression or to death from any cause (whichever occurs first)
Up to 3 years after the last participant's last dose of study treatment
Progression-free survival (PFS) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
PFS is defined as the time between randomization and the date of disease progression or death from any cause (whichever occurs first)
Up to 3 years after the last participant's last dose of study treatment
Time to objective response (TTOR) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
TTOR is defined as the time between randomization to the date of the first documentation of objective tumor response (CR or PR)
Up to 3 years after the last participant's last dose of study treatment
Number of participants with adverse events (AE)
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Number of participants with Serious AEs (SAEs)
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Number of participants with AEs leading to dose interruption, reduction, or discontinuation
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Number of deaths
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Overall Survival (OS)
Time Frame: Up to 3 years after the last participant's last dose of study treatment
OS is defined as the time between the randomization/the start of treatment to death due to any cause
Up to 3 years after the last participant's last dose of study treatment
Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score and symptom score
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Function Global Health Status functional scale score
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the EORTC-QLQ-F17 quality-of-life (QoL) functional scale score
Time Frame: Up to 28 days after the last dose of study treatment
Up to 28 days after the last dose of study treatment
Number of participants who achieve Objective Response (OR) as assessed by RECIST v1.1
Time Frame: Up to 3 years after the last participant's last dose of study treatment
Up to 3 years after the last participant's last dose of study treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bristol-Myers Squibb

Investigators

  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2025

Primary Completion (Estimated)

December 29, 2028

Study Completion (Estimated)

December 30, 2031

Study Registration Dates

First Submitted

February 27, 2025

First Submitted That Met QC Criteria

February 27, 2025

First Posted (Actual)

March 4, 2025

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CA240-0009
  • 2024-519814-29 (Other Identifier: EU CTR)
  • U1111-1315-9473 (Other Identifier: WHO)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

IPD Sharing Time Frame

See Plan Description

IPD Sharing Access Criteria

See Plan Description

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Clinical Trials on BMS-986504

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe